Local disease control after stereotactic body radiotherapy in patients with neuroendocrine neoplasms: a cohort study

References

• Singh S, Asa SA, Kennecke H, et al. Diagnosis and management of gastrointestinal neuroendocrine tumors: an evidence-based Canadian consensus. Cancer Treat Rev. 2016;47:32–45.
   PubMed Web of Science ®Google Scholar
• Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335–1342.
   PubMed Web of Science ®Google Scholar
• The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76:182–188.
   PubMed Web of Science ®Google Scholar
• Sorbye H, Welin S, Langer SW, et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol. 2013;24(1):152–160.
   PubMed Web of Science ®Google Scholar
• Tabaksblat E, Langer SW, Knigge U, et al. Diagnosis and treatment of bronchopulmonary neuroendocrine tumours: state of the art. Acta Oncol. 2016;55(1):3–14.
   PubMed Web of Science ®Google Scholar
• Kasajima A, Klöppel G. Neuroendocrine tumor G3 of bronchopulmonary origin and its classification. Pathol Int. 2022;72(10):488–495.
   PubMed Web of Science ®Google Scholar
• Janson ET, Knigge U, Dam G, et al. Nordic guidelines 2021 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. Acta Oncol. 2021;60(7):931–941.
   PubMed Web of Science ®Google Scholar
• Pavel M, Öberg K, Falconi M, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(7):844–860.
   PubMed Web of Science ®Google Scholar
• Hofland J, Kaltsas G, de Herder WW. Advances in the diagnosis and management of Well-Differentiated neuroendocrine neoplasms. Endocr Rev. 2020;41(2):371–403.
   PubMed Web of Science ®Google Scholar
• Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125–135.
   PubMed Web of Science ®Google Scholar
• Camus B, Cottereau AS, Palmieri LJ, et al. Indications of peptide receptor radionuclide therapy (PRRT) in gastroenteropancreatic and pulmonary neuroendocrine tumors: an updated review. J. Clin. Med. 2021;10:1–15.
   Web of Science ®Google Scholar
• Honma Y, Nagashima K, Hirano H, et al. Clinical outcomes of locally advanced esophagal neuroendocrine carcinoma treated with chemoradiotherapy. Cancer Med. 2020;9(2):595–604.
   PubMed Web of Science ®Google Scholar
• Iwata T, Ueno H, Itami J, et al. Efficacy of radiotherapy for primary tumor in patients with unresectable pancreatic neuroendocrine tumors. Jpn J Clin Oncol. 2017;47(9):826–831.
   PubMed Web of Science ®Google Scholar
• Wegner ER, Abel S, Colonias A. Stereotactic ablative body radiotherapy versus conventionally fractioned radiotherapy for early stage large cell neuroendocrine carcinoma of the lung. Lung Cancer Manag. 2020;9(3):LMT32.
   PubMedGoogle Scholar
• Chen KS, Lawhn-Heath C, Behr S, et al. Outcomes after high-dose radiation in the management of neuroendocrine neoplasms. PLoS ONE. 2021;16(6):e0252574.
   PubMed Web of Science ®Google Scholar
• Waldum HL, Öberg K, Sørdal ØF, et al. Not only stem cells, but also mature cells, particularly neuroendocrine cells, may develop into tumours: time for a paradigm shift. Therap Adv Gastroenterol. 2018;11:175628481877505.
   Web of Science ®Google Scholar
• Mahadevan A, Blanck O, Lanciano R, et al. Stereotactic body radiotherapy (SBRT) for liver metastasis – clinical outcomes from the international multi-institutional RSSearch® patient registry. Radiat Oncol. 2018;13(1):26.
   PubMedGoogle Scholar
• Soldà F, Lodge M, Ashley S, et al. Stereotactic radiotherapy (SABR) for the treatment of primary non-small cell lung cancer; systematic review and comparison with a surgical cohort. Radiother Oncol. 2013;109(1):1–7.
   PubMed Web of Science ®Google Scholar
• Guckenberger M, Andratschke N, Dieckmann K, et al. ESTRO ACROP consensus guideline on implementation and practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer. Radiother Oncol. 2017;124(1):11–17.
   PubMed Web of Science ®Google Scholar
• Myrehaug S, Hallet J, Chu W, et al. Proof of concept for stereotactic body radiation therapy in the treatment of functional neuroendocrine neoplasms. J. Radiosurg SBRT. 2020;6:321–324.
   PubMed Web of Science ®Google Scholar
• Chan DL, Thompson R, Lam M, et al. External beam radiotherapy in the treatment of gastroenteropancreatic neuroendocrine tumours: a systematic review. Clin Oncol. 2018;30(7):400–408.
   Web of Science ®Google Scholar
• Lo H, Abel S, Finley G, et al. Surgical resection versus sterotactic body radiation therapy in early stage bronchopulmonary large cell neuroendocrine carcinoma. Thorac Cancer. 2020;11(2):305–310.
   PubMed Web of Science ®Google Scholar
• Khalil A, Knap MM, Møller DS, et al. Local control after stereotactic body radiotherapy of centrally located lung tumours. Acta Oncol. 2021;60(8):1069–1073.
   PubMed Web of Science ®Google Scholar
• Hudson JM, Chung HTK, Chu W, et al. Stereotactic ablative radiotherapy for the management of liver metastases from neuroendocrine neoplasms: a preliminary study. Neuroendocrinology. 2022;112(2):153–160.
   PubMed Web of Science ®Google Scholar